Boehringer Ingelheim is in hot water for allegedly withholding data that could have prevented up to 40 percent of deaths and adverse reactions associated with use of its blood thinner drug Pradaxa.
Boehringer Ingelheim is in hot water for allegedly withholding data that could have prevented up to 40 percent of deaths and adverse reactions associated with use of its blood thinner drug Pradaxa.
Share this Article
Recommended